[Not Available].

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bulletin de l'Académie Nationale de Médecine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 27356366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

  2015cited by this paper
• Current efforts and trends in the treatment of NASH.

  2015cited by this paper
• Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD

  2015cited by this paper
• NASH, from diagnosis to treatment: Where do we stand?

  2015cited by this paper
• Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

  2015cited by this paper
• Gut-adipose tissue axis in hepatic fat accumulation in humans.

  2014cited by this paper
• Interactions between the intestinal microbiome and liver diseases.

  2014cited by this paper
• Association of adipose tissue and liver fibrosis with tissue stiffness in morbid obesity: links with diabetes and BMI loss after gastric bypass.

  2014cited by this paper
• Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH

  2013cited by this paper
• Alcohol-attributable mortality in France.

  2013cited by this paper
• Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.

  2013cited by this paper
• NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD

  2013cited by this paper
• Intestinal microbiota in patients with nonalcoholic fatty liver disease

  2013cited by this paper
• Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.

  2012cited by this paper
• The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.

  2012cited by this paper
• Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

  2011cited by this paper
• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality

  2011cited by this paper
• Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

  2010cited by this paper
• Diagnosis of different liver fibrosis characteristics by blood tests in non‐alcoholic fatty liver disease

  2010cited by this paper
• Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease

  2009cited by this paper
• Epidemiology and natural history of non-alcoholic steatohepatitis.

  2009cited by this paper
• Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

  2008cited by this paper
• High Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Morbid Obesity: A Contributor to Severe Hepatic Steatosis

  2008cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis

  2007cited by this paper
• Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

  2006cited by this paper
• Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

  2006cited by this paper
• In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

  2006cited by this paper
• Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.

  2005cited by this paper
• Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption

  2004cited by this paper
• Serum markers detect the presence of liver fibrosis: a cohort study.

  2004cited by this paper
• A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C

  2003cited by this paper
• Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

  2002cited by this paper
• Treatment of obesity: need to focus on high risk abdominally obese patients

  2001cited by this paper

• No citing papers are available for this paper.